基础化学第十五章(综述和论文的撰写).ppt

第十五章 综述和论文的撰写 一、怎样写科学论文 1、科学论文的写作程序 2、科学论文的结构 二、论文的发表程序 1、论文递交（Submission） 2、给编缉的信 3、修回 4、接受、校稿、发表 1 科学论论文的写作程序 n立题题 n查阅查阅 相关文献：图书馆图书馆 ，INTENET n获获得资资料和整理素材 n文章写作 n修改和发发表 2 研究型科学论文的结构 题目(Title)：概括全文，引起读者注意的一句话 作者(Authors)：联系方法，通讯作者用“*” 标记在 右上角。依托单位(Organization)，地区（邮编）， 国家 摘要(Abstract)： 50-200字，全文内容的高度浓缩 关键词(Key Words) ：3-5个词，可作为内容的索引 正文： 致谢(Acknowledgements) ：1、各类基金的资助 2、其 他相关人员的帮助 参考文献（References）：在文末写上 3 正文的结构和注明 前言：本文工作的原因、意义、和其他人工 作的关系/联系（为什么写此文） 内容包括： （1）图表：图表名、坐标轴标明、符号说 明、图表解释 （2）引用：注明来源和出处 讨论：这些结果说明了什么 结论： 4 文献 n课课本 n参考书书： n科技杂杂志 n学位论论文 5 网络普通搜索引擎 6 7 8 9 10 参考文献的引述方法 正文: .某些铜蓝蛋白极度缺乏的威尔逊病患者则 由于铁摄取不足，发生贫血症20。. 参考文献: 20.Askwith, C. and Kaplan, P. J. Trends Biochem. Sci., 1998, 23: 135-138. (作者)Arunlakshana, O.; Schild, H.O. (题目)Some quantitative uses of drug antagonists. (杂志名称)British Journal of Pharmacology. (年份)1959. (卷，期， Volume ，issue)14 (1), (页) 48 58. 11 综述型文章 1、介绍文献中的研究方法和结果 2、对介绍的方法或结果作评论 12 13 14 15 16 中文论文 题目: 3-取代-6-乙酰氧基莨菪烷的合成及其生 物活性研究 钮因尧，杨丽敏，崔永耀，朱亮，冯菊妹，陈红专，陆阳* （上海第二医科大学 药物研究所， 上海 200025） 摘要(中文)：整个论文内容的高度浓缩(以3-羟基-6- 乙酰氧基莨菪烷(5)为起始原料，合成4个新3-取代-6 -乙酰氧基莨菪烷。药理筛选结果表明6d对大鼠回肠 肌具有强激动活性；经M受体阻断剂阿托品的拮抗试 验，提示6d是潜在的M胆碱能受体激动剂。) 关键词(中文) ：包甲素类似物；M胆碱能激动剂；合 成 17 Synthesis and Bioactivities of 3Substituted 6- acetoxytropane Derivatives NIU Yin-Yao，YANG Li-Min，CUI Yong-Yao，ZHU Liang，LU Yang* (Institute of Materia Medica, Shanghai Second Medical University，Shanghai 200025) ABSTRACT：Four new 3substituted 6-acetoxytropane derivatives were synthesized from 3-hydroxy-6- acetoxytropane. The results of preliminary pharmacological tests showed that 6d had strong agonistic effect on ileal muscle of Guinea-pigs. With this agonistic effect being blocked by atropine, an exclusive muscarinic-receptor antagonist, we definitely believed that it was a potential muscarinic cholinergic agonist. Key Words：Analogs of Baogongteng A；muscarinic cholinergic agonist；synthesis 18 正文内容: 1.前言(Introduction) 包公藤甲素（Baogongteng A，1，简称包甲素），化学名为2- 羟基-6-乙酰氧基去甲莨菪烷1, 2，是上世纪70年代末从旋花 科（Convolvulaceae）植物丁公藤（Erycibe obtusifolia Benth） 中提取得到第一个具胆碱能活性的天然莨菪烷类生物碱（2）， 在临床上可用于治疗青光眼。通过兔虹膜、豚鼠回肠纵长肌M 胆碱能受体动力学研究，发现它是特异性M胆碱受体激动剂， 具有深入研发的广阔前景。1的类似物3无明显缩瞳活性3，而 4具有比1强的缩瞳活性，表明1中2-羟基对胆碱能活性影响很 小，而6-乙酰氧基是活性必需基团4。 天然1来源有限，而全合成1步骤多、总收率仅5%5,因此有必 要制备1的类似物用以筛选新药。 19 2.实验部分（不同杂志格式不同） 1合成实验 1.1 仪器与试剂 红外光谱用Nicolet-Magna IR750型仪测定；核磁共振 氢谱用Bruck AM-400 NMR仪、Varian-EM360L型仪 测定；质谱用美国HP-5988 GC/MS仪测定；紫外 254nm下检测包甲素类似物。柱层析用硅胶H（颗粒度 100-200 mesh）（上海杜园精细化工有限公司）；薄 层层析用HSG（F254）硅胶板（青岛海洋化工厂）； 1.2 合成方法 20 3.结果和讨论(Results and Discussion) 3.1 合成6d反应条件的探讨 3.1.1 反应温度对产物得率的影响 21 4.结论(Conclusions) 6a6c不能激动M胆碱能受体，而 6d对M受体的 强激动作用与对照品卡巴胆碱相近，表明3位上的 磺酰氧基对激动活性的产生影响很大。这为深入研 究药物与M受体的构效关系，进一步测试其对各M 亚型代表性标本的药理活性，最终定向合成高效低 毒的缩瞳新药提供实验依据。 致谢：本项目由上海市教委学科建设专项基 金部分资助（JY2001）。 22 参考文献： 1 姚天荣，陈泽乃，等. 包公藤的化学研究I，缩瞳有效成分 包公藤甲素的分离和初步研究J. 药学学报，1979，14：731- 735. 2 姚天荣，陈泽乃，易大年，等. 包公藤的化学研究II，新缩 瞳药包公藤甲素的结构J. 药学学报，1981，16：582-588. 国际药学研究杂志 23 英文论文 24 25 26 27 28 Acknowledgments This study was supported by the National Natural Science Foundation of China (No. 30070860); the Key Project of Shanghai Municipal Science and Technology Commission (No. 03JC14064 and No 34319230) and the Project of Shanghai Municipal Education Commission (No. 02BZ30). We wish to present our grateful thanks to Municipal Science Emphasis Item (No. 34319230), MOST Item (No. 2002AA231011) for financial support. We also thank Dr. Xiao-Jun YAO and Dr. Xiao-Yun ZHANG of department of chemistry in Lanzhou University and Dr. Florent Barbault in Universit Paris 7 for their helps in CoMFA study. 29 二、论文的发表程序 1、论文递交 （1）中文论文：邮寄手稿 （2）英文论文一般网上递交（Submission on line）： Menuscript（原稿） Graphic Abstract（带图摘要） 2、给编缉(Editor)的信（cover letter） （1）中文论文：单位介绍信（盖公章） （2）英文论文：通讯作者给编缉的信 30 2.给编缉(Editor)的信（cover letter） 格式:写信人地址、收信人地址、日期 Dept. of Chemistry Shanghai Second Medical University 280 South Chongqing Road Shanghai 200025, P. R. China. Fax: 86E-mail: Prof. Masakatsu Shibasaki Graduate School of Pharmaceutical Sciences The University of Tokyo 7-3-1 Hongo, Bunkyo-ku Tokyo 113-0033, Japan Fax: +81 3 5684 5206 E-mail: bmclasiamol.f.u-tokyo.ac.jp July 8, 2005 31 Dear Prof. Masakatsu Shibasaki: I wish to submit the enclosed manuscript “Activity and QSAR Study of Baogongteng A and Its Derivatives as Muscarinic Agonists” for consideration and publication in the journal of “Bioorganic and Medicinal Chemistry Letters”. We promise that the work described has not been published and if this article is accepted and it will not be published elsewhere. Also, the manuscript has been explicitly approved by all authors and by the responsible authority (Institute of Materia Medica, Shanghai Second Medical University, Shanghai 200025, China). An early response will be very appreciated. Sincerely yours, Yang Lu, Professor Encl. four copies of manuscript and illustration 32 According to the requirement of the journal of “Bioorganic and Medicinal Chemistry Letters”, we suggest following specialists as the referees of our article: Prof. Zhide Hu Department of Chemistry, Lanzhou University, Lanzhou 730000, P.R. China Tel.: +86-931-891-2578;fax: +86-931-891-2582. E-mail address: Prof. Paola Cratteri Department of Pharmaceutical Sciences, University of Florence, via U. Schiff 6, I-50019 Sesto Fiorentino, Firenze, Italy Fax: 39 E-mail: paola.gratteriunifi.it 33 3、论文的修回 格式 写信人地址 收信人地址 日期 Dear Prof. Masakatsu Shibasaki: I am very thankful to the referees of “Bioorganic and Medicinal Chemistry Letters” for their helpful suggestions about our article “Activity and QSAR Study of Baogongteng A and Its Derivatives as Muscarinic Agonists”. 34 According to their opinions, we made some revision as follows: 1. Three more compounds (22-24) which were recently prepared and tested biologically in our laboratory were added into the test set to improve the validation of the CoMFA model. Their structures, observed and predicted agonistic activities were added into Table 1 and 3 respectively. The predicted results were also satisfactory. 2. We have explained about the applying of cross-validated values in the CoMFA study, and the method of alignment in more details in Figure 2. Although calculating cross-validated values for predicted pEC50 of each compound in Table 3 and Figure 3 is really an effective way for the models validation as it makes the model being more accurate, we applied q2 of the training set for the validation following general understanding of CoMFA method. At last, Although CoMSIA is an alternative method which is also helpful in constructing the SAR model, I want to explain that some interesting results have been derived by our preliminary CoMFA study which followed general procedures of this method. In fact, we still go on the synthesis of BGT-A derivatives for the screening of muscarinic agonists. Further CoMFA and CoMSIA studies with mor